Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients

American Journal of Medicine

Volumn 100, Issue 5, 1996, Pages 496-501

  Ribera, Esteve ^a,b   Ocaña, Imma ^a   De Otero, Jordi ^a   Cortes, Emilia ^a   Gasser, Isabel ^a   Pahissa, Albert ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIMONY DERIVATIVE; MEGLUMINE ANTIMONATE; STIBOGLUCONATE SODIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENT INFECTION; RELAPSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ADULT; AGED; ALLOPURINOL; ANIMALS; ANTIMONY; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; DATA INTERPRETATION, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; LEISHMANIASIS, VISCERAL; MALE; MEGLUMINE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOMETALLIC COMPOUNDS; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0030001468     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)89503-4     Document Type: Article

References (25)

1. Pearson RD, Wheeler DA, Harrison LH, Kay HD. The immunobiology of leishmaniasis. Rev Infect Dis. 1983;5:907-927.
2. World Health Organisation. AIDS, leishmaniasis dangers of class highlighted. TDR News. 1991;36:1.
3. Badaro R, Carvalho EM, Rocha H, et al. Leishmania donovani: an opportunistic microbe associated with progressive disease in three immunocompromised patients. Lancet. 1986;i:647-648.
4. Fernández-Guerrero ML, Aguado JM, Buzón L, et al. Visceral leishmaniasis in immunocompromised hosts. Am J Med. 1987;83:1098-1102.
5. Alvar J, Gutiérrez-Solar B, Molina R, et al. Prevalence of Leishmania infection among AIDS patients. Lancet. 1992;339:1427.
6. Martinez Fernández R, Garcia Diaz J de D, Gutiérrez Sánchez J, et al. Leishmaniasis visceral en pacientes adictos a drogas por via parenteral, VIH positivos. Med Clin (Barc). 1987;88:509-511.
7. Berenguer J, Moreno S, Cercenado E, et al. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). Ann Intern Med. 1989;111:129-132.
8. Montalbón C, Calleja JL, Erice A, et al. Visceral leishmaniasis in patients infected with human immunodeficiency virus. J Infect. 1990;21:261-270.
9. Altés J, Salas A, Riera M, et al. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature. AIDS. 1991;5:201-207.
10. Medrano FJ, Hernandez-Quero J, Jimenez E, et al. Visceral leishmaniasis in HIV-1 infected individuals: a common opportunistic infection in Spain. AIDS. 1992;6:1499-1503.
11. Ribera E, Cucurull E, Ocaña I, et al. Leishmaniasis visceral en pacientes con infeccion por VIH. Enferm lnfecc Microbiol Clin. 1995;13:73-79.
12. Peters BS, Fish D, Golden R, et al. Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q J Med. 1990;77:1101-1111.
13. Berens RL, Marr JJ, Nelson DJ, LaFon SW. Antileishmanial effect of allopurinol and allopurinol ribonucleoside on intracellular forms of Leishmania donovani. Biochem Farmacol. 1980;29:2397-2398.
14. Jha TK. Evaluation of allopurinol in the treatment of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg. 1983;77:204-207.
15. Kager PA, Rees PH, Wellde BT, Hockmeyer WT, Lyerly WH. Allopurinol in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg. 1981;75:556-559.
16. Chunge CN, Gachihi G, Muigai R, et al. Visceral leishmaniasis unresponsive to antimonial drugs.III. Succesful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg. 1985;79:715-718.
17. Dellamonica P, Bernard E, Le Fichoux Y, et al. Allopurinol for treatment of visceral leishmaniasis in patients with AIDS. J Infect Dis. 1989; 160:905-906.
18. Martinez S, Marr JJ. Allopurinol in the treatment of american cutaneous leishmaniasis. N Engl J Med. 1992;326:741-744.
19. Allopurinol ribonucleoside. Information for Clinical investigators. Research Triangle Park, NC: Burroughs Wellcome, 1984:3-12.
20. Kager PA, Rees PH, Manguyu FM, et al. Clinical, haematological and parasitological response to treatment of visceral leishmaniasis in Kenya. A study of 64 patients. Trop Geogr Med. 1984;36:21-35.
21. Jernigan JA, Pearson RD. Antiparasitic agents. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone, 1995:458-492.
22. Berman JD. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy and future strategies. Rev Infect Dis. 1988;10:560-586.
23. Winship KA. Toxicity of antimony and its compounds. Adv Drug React Ac Pois Rev. 1987;2:67-90.
24. Gasser RA, Magill AJ, Oster ChN, et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis. 1994;18:83-90.
25. Cortés E, Ribera E, Cucurull E, et al. Pancreatitis aguda por antimoniales en pacientes con leishmaniasis visceral e infección por VIH. Med Clin (Barc). 1995;104:578-580.